Answers are grounded in this paper and cite their sources.
Abstract γδ T lymphocytes are attractive effector cells for immunotherapy. In vitro, they can be expanded and kill efficiently a variety of tumor cells. The frequency and distribution of γδ T lymphocytes were compared in tumor lymph nodes of 51 patients with follicular lymphoma lymph nodes (FL-LNs) and 28 patients with inflammatory lymph nodes (I-LNs). γδ and CD8 T lymphocytes were less abundant in FL-LNs than in I-LNs (p ≤ 10−7). These lymphocytes were localized in the perifollicular zone outside of the tumor follicles. Perifollicular γδ T lymphocytes expressed CCR7, in contrast to peripheral blood γδ T lymphocytes and both perifollicular and peripheral blood γδ T lymphocytes expressed CXCR4. The very low number of perifollicular γδ T lymphocytes in FL-LNs could be explained in part by migratory problems because of absence of CCL19 expression in FL-LNs compared with I-LNs. Conversely, CCL21 and CXCL12 were similarly expressed in both FL-LNs and I-LNs. CCL19 and CCL21 were expressed in high endothelial venules and lymphatic vessels, whereas CXCL12 was expressed by stromal cells surrounding high endothelial venules and lymphatic vessels. Peripheral γδ T lymphocytes from 34 patients with FL, expanded with Phosphostim and IL-2 in vitro, had the same expansion capacity as those from healthy individuals. Thus, γδ T lymphocytes can be an attractive source for adoptive immunotherapy in patients with FL, providing they may home in tumor LNs.
No takes yet. Share an insight, caveat, or question.
Braza et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: